Milestone 5 definition

Milestone 5 means the achievement of worldwide aggregate Net Sales of the Product (inclusive of all Indications) of at least two hundred fifty million U.S. dollars ($250,000,000), calculated on a cumulative basis for all Calendar Years (or portion thereof), provided that Milestone 3 is achieved by or before December 31, 2030.

Milestone 5 means FDA approval of a NDA for FX301.

Milestone 5 has the meaning assigned to it in the Project Agreement.

Examples of Milestone 5 in a sentence

• Licensee shall launch a research and development program for the licensed therapeutic rights pursuant to the therapeutic milestone events and fees outlined below, unless Licensee executes a Sublicense Agreement as set forth in Milestone 5 in section 2.4 above.

• Should Licensee not execute a Sublicense Agreement as set forth in Milestone 5, Licensee shall pay a fee of *** to the Licensor and provide a detailed Commercialization Plan for the licensed therapeutic rights to Licensor within forty-five days of the Deadline for Milestone 5.

• To date, the Company has incurred costs of approximately Cdn $6.6 million towards Milestone 4, Cdn $4.2 million towards Milestone 5 and Cdn $2.4 million towards Milestone 6, of which $142 was recognized for milestone 5 during the quarter ended December 31, 2014 under this grant and $200 was recognized for milestone 6 during the quarter ended March 31, 2016.

• Milestone 1: Milestone 2: Milestone 3: Milestone 4: Milestone 5: Final Acceptance NOTE TO AGENCIES: Contract performance security may be used as a performance assurance tool.

• Distribution of Withdrawal Penalty revenue associated with Readiness Milestone 5 shall not be distributed to the remaining customers in that cluster until all customers in that cluster have reached Commercial Operation and thereafter shall be distributed as described above.

More Definitions of Milestone 5

Milestone 5 means cumulative Net Sales of the Product Candidate exceeding three hundred million dollars ($300,000,000), inclusive of Milestone #4, but only if the foregoing Milestone is achieved no later than the Milestone Target Date.

Milestone 5. [ ]* [ ]* Milestone 6: [ ]* [ ]*. Each milestone is independent, so that the achievement of any one milestone with respect to a Research Compound or Product does not require payment of lower numbered unachieved milestones with respect to that Compound or Product.

Milestone 5 means achievement of aggregate Annual Revenues by all Selling Parties of at least $12,000,000 during any Calendar Year ending on or before December 31, 2026.

Milestone 5. Clinical Trial Assay Build Completion (Including CTA QC and Control Specifications) This milestone entails activities required to complete development of the Clinical Trial Assay for use in Phase III Clinical Trial. The assay is planned to be presented to CDRH under an Investigational Device Exemption application. The following work packages will be competed; [**].

Milestone 5. CubeRover EM Integrated with Cable Reel Target Date: ATP + 10.5 Months Entrance Criteria: 1. CubeRover, Cable, and Reel Engineering Model Integration and Test Plan has been drafted. 2. CubeRover, Cable, and Reel Master Build Reports are complete. Success Criteria: 1. CubeRover, Cable, and Reel Engineering Model Integration and Test report uploaded to NASA server. 2. CubeRover, Cable, and Reel Engineering Model Integration and Test report reflects the as assembled & integrated CubeRover EM / Cable and Reel EM.

Milestone 5. COMPANY has issued a PURCHASE ORDER for delivery of a quantity of the 2GFuel that is at least the quantity of the Batch Volume specified in Table 3.A. above for the Initial Batch and CONTRACTOR delivers, on or before [***], at least the quantity of the Batch Volume specified in the Table 3.A. above for the Initial Batch meeting the applicable SPECIFICATIONS.

Milestone 5 shall be demonstrat:4 on by BIOTHERAPIES (to MICHIGAN's reasonable satisfaction) of the commencement o.f FDA Phase III clinical trials ---- for a theraoeutic Product. The following ~s the milestone achievement schedule. BIOTHERAPIES shall achieve demonstration of the milestones by -the dates set out below, and, upon any failure to do so, MICH7GAN may az Jts option terminate ~his-Agreement and the license rights conveyed herein: (1) Milestone 1: December 31, 1996; (2) Milestone 2: January 31, 1-997; (3) Milestone (4) Milestone 4: